The decision follows a positive recommendation received from the Committee for Medicinal Products for Human Use (CHMP) in November 2024.

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.

The Abu Dhabi Stem Cells Center (ADSCC) has developed clinical-grade induced pluripotent stem cells (iPSCs) that meet GMP protocols.

The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

Paclitaxel is under clinical development by InnoUp Farma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

MET-3 is under development for the treatment of hypertriglyceridemia. It comprises live microbiota that normally reside in the human gut of a healthy individual. It is administered through oral route ...

SRD-002 is under clinical development by Sardocor and currently in Phase II for Diastolic Heart Failure (HFpEF).

BG-102 is under clinical development by SL Bigen and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...